[go: up one dir, main page]

HK1069767B - 阻礙視覺的方法 - Google Patents

阻礙視覺的方法 Download PDF

Info

Publication number
HK1069767B
HK1069767B HK05101851.1A HK05101851A HK1069767B HK 1069767 B HK1069767 B HK 1069767B HK 05101851 A HK05101851 A HK 05101851A HK 1069767 B HK1069767 B HK 1069767B
Authority
HK
Hong Kong
Prior art keywords
ctgf
ocular
cells
expression
cell
Prior art date
Application number
HK05101851.1A
Other languages
German (de)
English (en)
French (fr)
Other versions
HK1069767A1 (zh
Inventor
David R. Hinton
Shikun He
Noelynn A. Oliver
Original Assignee
Fibrogen, Inc.
University Of Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen, Inc., University Of Southern California filed Critical Fibrogen, Inc.
Priority claimed from PCT/US2002/039777 external-priority patent/WO2003049773A1/en
Publication of HK1069767A1 publication Critical patent/HK1069767A1/zh
Publication of HK1069767B publication Critical patent/HK1069767B/zh

Links

HK05101851.1A 2001-12-11 2002-12-11 阻礙視覺的方法 HK1069767B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33954701P 2001-12-11 2001-12-11
US60/339,547 2001-12-11
PCT/US2002/039777 WO2003049773A1 (en) 2001-12-11 2002-12-11 Methods for inhibiting ocular processes

Publications (2)

Publication Number Publication Date
HK1069767A1 HK1069767A1 (zh) 2005-06-03
HK1069767B true HK1069767B (zh) 2012-06-22

Family

ID=

Similar Documents

Publication Publication Date Title
EP1463531B1 (en) Methods for inhibiting ocular processes
RU2734678C2 (ru) Генетическая конструкция
AU2004242586C1 (en) Method of treating corneal transplant rejection by using VEGF antagonists
US9504649B2 (en) Method and compositions for genetic and retinal disease
JP2002539082A (ja) 血管内皮増殖因子２
US6696415B2 (en) Treatment of ocular neovascularization and related diseases
EP2276501B1 (en) Methods and compositions for genetic and retinal disease
KR102379006B1 (ko) 망막 염증 치료에 사용하기 위한 작용제
EP3178485B1 (en) Socs1-derived peptide for use in chronic complications relating to diabetes
WO1999024056A1 (en) Regulation of ocular angiogenesis
US20130034555A1 (en) Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases
HK1069767B (zh) 阻礙視覺的方法
CA2371046A1 (en) Therapeutic compositions and methods for enhancing angiogenesis
US7300654B2 (en) Method of treating corneal transplant rejection in high risk keratoplasty patients
WO2006091930A2 (en) Methods and compounds for promoting vessel regression
US20080107714A1 (en) Use of a vector comprising a nucleic acid encoding an anti-angiogenic factor for the treatment of corneal neovascularization
Wang et al. Receptor tyrosine kinase inhibitors AG013764 and AG013711 reduce choroidal neovascularization in rat eye
CN113645994A (zh) 使用色素上皮衍生因子(pedf)治疗疾病的方法
US20240076694A1 (en) Composition comprising raav containing soluble vegfr-1 variant cdna for treatment of macular degeneration
US20080287384A1 (en) Methods of Identifying Agents Having Antiangiogenic Activity
Ferrer Highlights from the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2008: eyes on Innovation
Sakurai et al. AdrenomedullineReceptor Activity-Modifying Protein 2 System Ameliorates Subretinal Fibrosis by Suppressing Epithelial-Mesenchymal Transition in Age-Related Macular Degeneration
WO2008065429A1 (en) Method for delivering gene therapy vectors to the optic nerve head